Genome Biologics

Genome Biologics is a biotech startup founded in 2017 with a mission to develop innovative RNA interference (RNAi) therapies for cardiovascular and cardiometabolic diseases. They have pioneered cutting-edge RNAi interventions tailored for specific tissues to target the transcriptome of these diseases, addressing a vital need in the medical field. Their state-of-the-art technology platforms allow for the expedited creation of RNAi therapies, offering promising solutions where current treatments are ineffective or absent. Genome Biologics presents an exciting opportunity for venture capitalists seeking to invest in the forefront of biotechnology and medical innovation.